文献速递膀胱癌与上尿路尿路上皮癌

特瑞普利单抗联合吉西他滨顺铂新辅助治疗肌层浸润性膀胱癌的II期临床试验

Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined With Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial.
PubMed 文献 · J Urol · 2026-02-17

该II期试验纳入30例T2-3N0M0肌层浸润性膀胱癌患者,接受特瑞普利单抗联合吉西他滨顺铂新辅助治疗4周期后行根治性膀胱切除术。27例可评估患者pCR率达40.7%,≥3级不良事件发生率13.3%,显示良好疗效与安全性。

要点

  • 特瑞普利单抗联合GC方案新辅助治疗MIBC的pCR率为40.7%。
  • ≥3级不良事件发生率为13.3%,安全性可接受。
  • KMT2D/ERBB2/EPHA2双突变患者pCR率较低。

核心结论

  • 特瑞普利单抗联合吉西他滨顺铂新辅助治疗肌层浸润性膀胱癌显示出良好的疗效和安全性,是有前景的治疗策略。

研究设计与样本

  • II期临床试验,纳入30例拟行根治性膀胱切除术的T2-3N0M0肌层浸润性膀胱癌患者。
  • 治疗方案为特瑞普利单抗240 mg、吉西他滨1000 mg/m2、顺铂70 mg/m2第1天,吉西他滨1000 mg/m2第8天,21天为一周期,共4周期。
  • 末次治疗周期后4至6周行根治性膀胱切除术,主要终点为病理完全缓解(pCR)。

主要发现

  • 27例患者在新辅助治疗后行根治性膀胱切除术,3例退出研究。
  • pCR率达40.7%(11/27)。
  • 1年和3年无进展生存率分别为85.2%和77.6%;1年和3年总生存率分别为96.2%和84.6%。
  • 18例新辅助治疗期间保留目标病灶的患者中,pCR率为27.8%(5/18),病理缓解率为50.0%(9/18)。
  • ≥3级不良事件发生率为13.3%。

关键数值与推荐

  • KMT2D、ERBB2或EPHA2基因双突变患者新辅助治疗后pCR率较低。
  • PD-L1表达≥5%患者(n=16)pCR率为43.8%(7/16),病理缓解率为68.8%(11/16)。
  • PD-L1表达<5%患者(n=11)pCR率为36.4%(4/11),病理缓解率为63.6%(7/11)。

临床怎么用

  • 该联合方案可作为肌层浸润性膀胱癌新辅助治疗的候选方案,但需进一步验证。
  • KMT2D、ERBB2或EPHA2双突变及PD-L1表达状态可能有助于筛选获益人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the efficacy and safety of toripalimab combined with gemcitabine and cisplatin as the neoadjuvant treatment (NAT) before radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: This phase II trial enrolled 30 patients with T2-3N0M0 MIBC scheduled for RC. Patients received a treatment regimen of toripalimab 240 mg, gemcitabine 1000 mg/m2, and cisplatin 70 mg/m2 on day 1, followed by gemcitabine 1000 mg/m2 on day 8, in 21-day cycles for a total of 4 cycles. RC was scheduled 4 to 6 weeks after the last treatment cycle. The primary end point is the pathological complete response (pCR), and the secondary end points are safety, overall survival, and progression-free survival. The Fisher exact test test was performed to analyze the relationship between genomic changes, tumor mutation burden, and pCR rate. RESULTS: From January 2020 to December 2021, 27 patients underwent RC after NAT, and 3 withdrew from the study. The pCR rate reached 40.7% (11/27). The 1-year and 3-year progression-free survival rates were 85.2% and 77.6%, respectively; the 1-year and 3-year overall survival rates were 96.2% and 84.6%, respectively. Among the 18 patients who retained the target lesions during NAT, the pCR rate was 27.8% (5/18) and the pathological response rate was 50.0% (9/18). The rate of adverse events of grade 3 or higher was 13.3%. Biomarker analysis indicated that patients with dual-mutation in KMT2D, ERBB2, or EPHA2 genes had a lower pCR rate following NAT. In the patients with PD-L1 expression ≥ 5% (n = 16), the pCR and pathological response rate were 43.8% (7/16) and 68.8% (11/16), respectively. In patients with PD-L1 expression < 5% (n = 11), the pCR rate was 36.4% (4/11) and the pathological response rate was 63.6% (7/11). CONCLUSIONS: Toripalimab combined with gemcitabine and cisplatin chemotherapy demonstrates a good efficacy and safety, making it a promising therapeutic strategy for NAT of MIBC. TRIAL REGISTRATION: The clinical trial number for this study is ChiCTR2100051298.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Zhang S, Li T, Li D, et al. Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined With Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial. J Urol. 2026. PMID: 41701948. doi:10.1097/JU.0000000000004993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。